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Abstract
This year marks 40 years since the technique was designed of measuring and monitoring the
basic haemodynamic parameters in humans by means of impedance cardiography (ICG), also
known as impedance plethysmography of the chest, electrical bioimpedance of the chest or
reocardiography. The method makes it possible to denote stroke volume and cardiac output.
It also enables the factors to be assessed that influence the following: preload (measurement of
thoracic fluid content), afterload (measurement of systemic vascular resistance), the systemic
vascular resistance index, contractibility (measurement of the acceleration index), the velocity
index, the pre-ejection period, left ventricular ejection time, systolic time ratio and heart rate.
Advances in hardware and software, including digital signal tooling and new algorithms,
have certainly improved the quality of the results obtained. The accuracy and repeatability of
the results have been confirmed in comparative studies with results obtained through invasive
methods and echocardiography. Not only are haemodynamic changes monitored by means of
ICG in intensive care units, in operating theatres and at haemodialysis stations, but repeated
measurements also provide haemodynamic information during the treatment of patients with
hypertension and heart failure and pregnant women with cardiological problems and gestosis.
A single ICG investigation makes a great contribution to the basic information available about
the circulatory system, which is helpful in the initial evaluation of patients in a severe general
condition (for example in the admission room), and also makes it possible to make a swift
diagnosis of the cause of complaints such as dyspnoea and hypotonia. A particular application
of ICG is the assessment of haemodynamic parameters during the programming of atrioven-
tricular and CRT pacemakers. Besides these uses, ICG is a valuable investigative tool. It is
defect-free and does not have pulmonary artery pressure monitoring limitations. Moreover, it
is not as time-consuming as echocardiography and the examination can be performed by
trained technicians or nurses. (Cardiol J 2007; 14: 115126)
Key words: impedance cardiography, electrical bioimpedance of the chest,
reocardiography, cardiac output, haemodynamics, non-invasive diagnostics
Introduction
Evaluation of the haemodynamic state of a pa-
tient has always been a subject of interest to clini-
cians. Hitherto it has been somewhat difficult to ob-
tain haemodynamic data and invasive techniques
have usually been needed. These techniques are ex-
pensive, time-consuming, demand complicated
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equipment and trained staff and are not always pos-
sible to use because of the condition of the patient,
which may be either too severe or else too good to
run the risks associated with invasive techniques.
The widespread increase in diseases of  the circu-
latory system and progress in the diagnostics and
the therapy of heart disease have made it neces-
sary to introduce and propagate, on a greater scale
than previously, cheap and non-invasive methods
of measuring haemodynamic parameters. Non-in-
vasive methods such as magnetic resonance imag-
ing or echocardiography and methods such as radi-
onuclide angiography which involve minimum in-
vasiveness are unfortunately quite complicated and
demand a separate laboratory, to which it may be
difficult to transport severely ill patients. Thanks to
these methods single measurements may be made
which have an application in diagnosis and evalua-
tion at a certain moment in the treatment but which
are not suitable for the continuous monitoring of
a patients state. In this respect impedance cardiog-
raphy offers a new standard of treatment and ena-
bles continuous bedside measurements to be made.
What is impedance cardiography?
Impedance cardiography (ICG) is a non-invasive
method of evaluating haemodynamic parameters [1].
Other terms found in the literature to describe ICG are
impedance plethysmography of the chest, electric
bioimpedance of the chest or reocardiography [2].
The haemodynamic parameters
assessed by impedance cardiography
Through the use of ICG the state of the circu-
latory system and trends in changes in haemody-
namic parameters can be assessed easily, quickly,
cheaply and, most importantly, non-invasively. The
method makes possible the denotation of stroke vol-
ume (SV) and stroke index (SI). It also enables the
factors to be assessed that influence the following:
 preload  the measurement of thoracic fluid
content (TFC);
 afterload  the measurement of systemic vas-
cular resistance (SVR);
 the systemic vascular resistance index (SVRI);
 contractibility  the measurement of accelera-
tion index (ACI);
 the velocity index (VI);
 the pre-ejection period (PEP);
 left ventricular ejection time (LVET);
 systolic time ratio (STR);
 heart rate (HR).
How impedance cardiography works?
The method is based on changes in the elec-
trical resistance of the chest during heartbeat [1].
The following changes occur during the outflow of
blood from the heart and influence the impedance
signal registered: enlargement of the volume of the
aorta, enlargement of the volume of the blood in the
pulmonary circulation and laminar blood flow in the
large vessels [3]. With the electrical current fre-
quencies used in ICG (10 kHz to 100 kHz) erythro-
cytes, in general, do not conduct an electrical cur-
rent. When at rest, Brownian motions hold their
accidental orientation. The electrical current which
is flowing along the vessel must flow around the red
blood cells, which causes low electrical conductiv-
ity. The laminar flow causes an erythrocyte arrange-
ment parallel to the flow direction and the electri-
cal current then meets smaller cross-section sur-
faces, which results in higher conductivity [2]. In
modern ICG systems eight electrodes are used
(four electrodes delivering the electrical current,
known as the current electrodes, and four elec-
trodes registering the voltage changes, the volt-
age electrodes). The electrodes are positioned
symmetrically on both sides of the patients neck
(on the neck the current electrodes lie above the
voltage electrodes), and on both sides of the chest
on the mid-axillary line on a level with the xiphoid
process (on the chest the current electrodes lie
below the voltage electrodes). An alternating cur-
rent of low intensity (4 mA, 60 kHz) flows along the
four current electrodes, while the next four elec-
trodes, the voltage electrodes, which are situated
internally to the current electrodes, register tem-
porary changes in voltage [1, 4]. These electrodes
are also used for ECG registration.
As a result of Ohms law, when the current
of constant intensity flows through the chest, the
changes in voltage are directly proportional to the
changes in resistance. The entire resistance of
the chest, known as the basic resistance (Z0), is
the sum of the resistance of each of the compo-
nents of the chest: the adipose tissue, the heart
and skeletal muscles, the lungs, vessels, bones
and air [1]. Changes in the resistance of the chest
result from changes in the volume of the lungs
during respiration and from changes in the vol-
ume and blood velocity in the large vessels dur-
ing systole and diastole. Changes in resistance
caused by breathing are eliminated by the use of
electronic filters [1, 5, 6], and changes in resist-
ance associated with an outflow of blood are tak-
en into consideration (DZ).
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From the graph of the resistance changes of the
chest (the impedance cardiogram graph: DZ) the
next graph, that of its first derivative (DZ/Dt), is ob-
tained, on which waves and points are visible which
are used for further calculations. ECG tracing, ob-
tained from the electrodes described above, is also
needed. The curve is usually constructed in such
a way that the fall in impedance causes an increase
in the value on the Y-axis, a convention which re-
flects changes in conductivity. The polarity of the
curve of the first derivative of the impedance is the
same as the impedance curve [3].
On the graph of the first derivative of changes
in impedance the following waves are distinguished:
A, B, C, (DZ/Dt wave maximum), X, Y, O. The A
wave appears between the beginning of the P wave
and the beginning of the QRS complex and is linked
to changes in volemia during atrial contraction. Next
is the B wave, which appears simultaneously with
the opening of the aortic valve. The next wave is
known as DZ/Dt and corresponds to the peak of aor-
tic flow, and this reflects the rapidity of changes in
the blood flow through the aortic valve during left
ventricle systole. It has been ascertained, however,
that the DZ/Dt wave is also caused by changes in pul-
monary artery flow during right ventricle systole [2].
According to Ito [7], the DZ/Dt wave reflects
changes in the volume both in the ascending aorta
and in the pulmonary trunk. The aorta has a sever-
al times greater influence on the value of the DZ/Dt
wave than the pulmonary trunk. According to Thom-
sen et al. [8], changes in impedance are caused in
80% of cases by the aorta. The DZ/Dt wave ends with
the X wave, which is convergent with the aortal com-
ponent of the II tone and with aortic valve closure.
In the diastole a round, flat O wave appears in
some patients [2]. Lababidi et al. [9] stated that this
wave appeared in cases of mitral stenosis within the
mitral valve opening. In other research the O wave
was observed in patients with left ventricle dysfunc-
tion, especially diastolic. This wave was diminished
after a change in body position or after treatment
which diminished preload. The O wave in patients
with severe heart failure is less susceptible to the
above-mentioned procedure. It is suggested that
the presence of the O wave has a prognostic value,
and its changes can be used as an indicator of the
effectiveness of the therapy [1012].
One of three points of the impedance cardio-
gram is accepted as the beginning of the cardiac
outflow: 1) the end of the B wave, 2) the crossing
point of the DZ/Dt wave and the zero line, 3) the
point where the dZ/dt signal is increased by 15%
of the DZ/Dt wave maximum of the impedance
cardiogram. The end of the outflow is usually defined
as point X of the DZ/Dt signal [2]. The parameters of
the outflow listed are continuously displayed on the
screen of the device, so that it is possible to monitor
the haemodynamic parameters from beat to beat.
Stroke volume: the key-parameter
assessed by means of
impedance cardiography
The notion of non-invasive monitoring of
haemodynamic parameters appeared in 1940s [13],
when Nyboer et al. [13] found a relationship be-
tween changes in impedance (DZ), basic impedance
(Z0) and the volume of the area investigated (DV),
which they represented with the example:
where p is the specific resistance of blood and L is
the length of the chest. Nyboer et al. used the method
of impedance cardiography to evaluate the flow of
blood in limbs [2].
In the 1960s Kubicek et al. [14] received a com-
mission from NASA to work out a non-invasive
method of assessing cardiac output (CO). The re-
sult of the teams work was the construction of the
impedance cardiograph and the definition of a new
equation determining SV. The equation included the
maximum value of the first derivative of the imped-
ance curve (DZ/Dtmax) and the time of the outflow
from the left ventricle (LVET, left ventricular ejec-
tion time):
In the 1980s, Sramek [15] worked out a new
equation for counting the SV using the model of the
truncated cone of the chest instead of the cylindri-
cal model used by Kubicek et al. Simultaneously, it
was proposed to accept as value L (the length of the
chest) 17% of the height of the patient (H). The new
equation was as follows:
In 1986 Bernstein [16] modified the Sramek
equation, introducing the term d (the relation of the
actual weight to the so-called ideal weight). The aim
of the modification was a more exact definition
DV = p ×        × DZL
2
Z
2
0
SV = p ×         ×               × LVET
L
2
Z
2
0
DZ
Dt max
SV =                         ×                 × LVET
DZ
Dt max(0.17 × H)3
4.2 Z0
118
Cardiology Journal 2007, Vol. 14, No. 2
www.cardiologyjournal.org
of the volume of the chest. The new equation was
presented as follows:
In spite of the improvements made by Sramek
[15] and Bernstein [16], the manner of obtaining and
converting the impedance signal and simplifications
accepted in the algorithms led to results which were
not uniform, variable and weakly correlated with
invasive methods (thermodilution and the Fick
method) [17]. It seemed that the ICG method, con-
sidered not very reliable, would not find application
in clinical practice [18, 19]. However, progress in
obtaining and converting the signal and new algo-
rithms of calculating the outflow of the heart led to
impedance cardiography becoming a new and valu-
able investigative tool.
Progress in hardware and software, such as the
formulation of the CardioDynamics digital tooling
of the signal (the DISQ digital impedance signal
quantifier and the creation of that companys own
patented modification of the Sramek and Bernstein
equation, known as the ZMARC algorithm: Modu-
lating AoRtic Compliance), did indeed improve the
quality of the results obtained. The latest types of
device, such as the CardioDynamics BioZ, are char-
acterised by their precision and the repeatability of
their results, as confirmed in clinical research.
Moreover, the results are comparable to those ob-
tained with invasive methods [1, 5, 19, 2023]. The
CO evaluated by means of impedance cardiography
(BioZ ICG monitor, CardioDynamics, San Diego,
California) was closely correlated with measure-
ments using thermodilution in patients with both
benign and severe heart failure [5].
Van Da Water et al. [20] showed that CO cal-
culated with the use of the ZMARC equation had
the greatest compatibility with that qualified in the
use of thermodilution. In other clinical research in
which this algorithm was used a lineal dependence
and an acceptable degree of deviation between ICG
and thermodilution was determined [22, 23].
Beside devices made by BioZ System, Cardio-
Dynamics, San Diego, impedance cardiographs made
by other companies, such as the IQTM System, Wan-
tagh Incorporated, Bristol and SORBA Medical Sys-
tems, Inc., Brookfield are available on the market.
Advantages of impedance cardiography
The advantages of ICG include its non-inva-
siveness, relief of burden to the patient, speed
in obtaining results (a result at the bedside) and
the low cost of the testing [24]. ICG can replace in-
vasive methods of evaluating haemodynamic param-
eters and this can be done in all circumstances, in-
cluding ambulatory treatment [25, 26]. Currently
ambulatory assessment is possible, for example at
a patients home, when, earlier, hospitalisation
would have been required. The data obtained ena-
ble intervention to take place quickly, such as initi-
ating suitable pharmacotherapy and making appro-
priate modifications to the medicaments and doses
already instituted. Verhoeve et al. [27] showed a high
degree of repeatability of measurements obtained
by means of ICG during the same day.
The aggravation of heart failure is linked to
a fall in basic chest resistance because of pulmo-
nary compensation, which can easily be detected by
means of ICG. It has been demonstrated that the
basic resistance of the chest (Z0) is closely corre-
lated with radiographic changes [2830]. Milzman
et al. [31] proved that Z0 < 19 W has a sensitivity of
90% and a specificity of 94% in recognising radio-
logical pneumono-oedema; Z0 below 18.5 W indicates
interstitial pulmonary oedema and below 14.8 W pul-
monary oedema. The efficiency of pulmonary hae-
mostasis therapy can be assessed on the basis of
an increase in the value of Z0 [32].
Clinical application
of impedance cardiography
Impedance cardiography in hypertension
ICG is used in the diagnostics and treatment of
hypertensive patients [1, 3238]. Although arterial
hypertension is defined as elevated values of arterial
blood pressure, it is also associated with abnormal CO,
resistance, and susceptibility of the arteries. Arterial
susceptibility can be calculated as the relation of SV
to pulse pressure (i.e. the difference between systo-
lic and diastolic arterial pressure) [39, 40].
These haemodynamic aspects of arterial hyper-
tension have an influence on the diagnosis, risk
assessment and treatment. Measurements of
haemodynamic parameters enable the circulatory
system to be better assessed, offer a greater possi-
bility of recognising high-risk patients and enable
treatment to be selected more appropriately.
Arterial blood pressure is not an indicator
which characterises the whole circulatory system.
Mean arterial pressure (MAP) is a product of two
components: CO and SVR. Arterial hypertension
can be a result of an increase in CO, SVR or both.
Haemodynamic measurements allow patients with
elevated CO to be distinguished from those with
max
DZ
Dt
SV = d ×                        ×                 × LVET
(0.17 × H)3
4.2 Z0
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elevated SVR as a cause of the arterial hyperten-
sion [41].
Linb and Eisenberg [42], using non-invasive
evaluation of the circulatory system by means of
ICG in patients with arterial hypertension, report-
ed a good reaction to a beta blocker (propranolol)
in patients with raised CO and the efficiency of va-
sodilatators of the calcium blocker group (nifed-
ipine) in patients with elevated SVR. In the course
of time CO usually diminishes and SVR increases.
In young adults, hypertension is more often
associated with increased CO, while in older peo-
ple it is linked with increased SVR. ICG can be used
for risk assessment of possible complications of ar-
terial hypertension. Galarza et al. [43] examined pa-
tients with arterial hypertension after cerebral
stroke and patients with arterial hypertension with-
out a history of stroke. They showed that in the
former group CO was diminished and SVR was in-
creased. These differences appeared in spite of
identical blood pressure in both groups and the
same antihypertensive treatment.
ICG has been used to assess non-pharmacolog-
ical treatment in patients with benign arterial hy-
pertension. In patients on a low-sodium diet it was
ascertained that a diminishing of SV, a decrease in
diastolic arterial blood pressure and an increase in
the impedance of the chest (decreased TFC) was
consistent with a diminution in the volume of ex-
tracellular fluid [44]. Measurements of haemody-
namic parameters can be useful in the choice of
antihypertensive treatment, dose selection and
evaluation of the efficiency of the treatment. Sev-
eral pieces of research have shown that therapy
applied on the basis of ICG data has improved arte-
rial blood pressure control.
Taler et al. [45] examined 104 patients with
insufficient blood pressure control, using two or
more antihypertensives. The patients were ran-
domised into two groups: a group which was treat-
ed according to ICG findings and a group where the
standard treatment was used. Proper blood pres-
sure control (defined as achieving blood pressure
below 140/90 mm Hg) was obtained 70% more of-
ten in the group treated according to ICG findings.
In these patients a greater reduction in SVR was
obtained and more intensive diuretics were used in
treatment based on the level of TFC.
In patients with refractory arterial hyperten-
sion defined as systolic blood pressure of over
140 mm Hg or diastolic blood pressure of over
90 mm Hg, Sharman et al., [46] through treatment
with two antihypertensive medicines, obtained good
blood pressure control in 57.1% of patients who had
not been treated earlier according to ICG data.
Sramek et al. [47] also reported that by ICG the
optimum antihypertensive treatment [47] can be
chosen more easily. Deviations in values from the
haemodynamic parameters may indicate patients who
have interrupted the treatment or the occurrence of
complications such as a worsening of kidney function
[35]. A deterioration in heart function obtained by ICG,
through the VI or STR for instance, may be the first
signal of development of left ventricle failure.
Other applications of impedance cardiography
ICG can be useful in diagnosis and making ther-
apeutic decisions in such clinical situations as dysp-
noea [1, 48], pulmonary hypertension [4], mechani-
cal ventilation [49], care after by-pass surgery [20, 22,
50, 51] and other operations, in intensive care units
[21, 5257], in dialysed patients [21, 5864] and with
heart pacemakers for the purpose of evaluation of SV
and the optimisation of pacing parameters [6574].
Impedance cardiography in cardiosurgery
Studies have been performed which indicate
the possibility of using ICG in patients with a me-
chanical left ventricle assist device [75]. ICG was
used to monitor haemodynamics during surgical
operations [7678]. Appraisal for surgical interven-
tion and the optimisation of circulatory system pa-
rameters before intervention, especially in the eld-
erly, are also possible by means of ICG.
Several authors have reported using ICG and
qualifying contractibility parameters in the diagnos-
tics of coronary heart disease. Indeed, lower con-
tractibility parameters (ACI, dZ/dt were observed
both at rest and during effort in patients with coro-
nary heart disease than in those without. The in-
teresting point is that no differences in SV were
found between these groups [79, 80].
Impedance cardiography during pregnancy
ICG has proved useful for monitoring changes
in parameters of the circulatory system in pregnant
women [8183] and also in infants, babies and chil-
dren, because this method can be used successful-
ly with patients who are too small for pulmonary
artery catheterisation and, most importantly, it is
not associated with a risk of complications. ICG has
been used with children receiving chemotherapy to
evaluate cardiac dysfunction [84].
Impedance cardiography during
cardiac pacemaker programming
Great hopes have been pinned on the use of
ICG for obtaining the optimum atrioventricular setting
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in DDD pacemakers [6469] and ICG is becoming
a method of optimising CRT pacemakers [7074].
Impedance cardiography in
differentiating the reasons for dyspnoea
Springfield et al. [48] indicated that ICG as
a useful tool in the differential diagnostics of pa-
tients with dyspnoea. By ICG the authors obtained
significant differences in the cardiac index (CI)
(2.2 vs. 3.1; p < 0.0001), STR (0.52 vs. 0.37;
p < 0.01) and VI (32.9 vs. 42.7; p < 0.01) between
patients with cardiogenic and those with non-car-
diogenic dyspnoea.
Therapy monitored by
impedance cardiography
Albert et al. [85] emphasised that the availa-
bility of haemodynamic data influences the manner
of treatment. In a study conducted on patients with
low CO, continuous cardiac performance monitor-
ing increased the number of therapeutic decisions
and shortened the time of hospitalisation by an av-
erage of two days.
ED-IMPACT study results (the Emergency
Department IMPedance Cardiography-aided As-
sessment Changes Therapy) indicate that haemo-
dynamic data obtained by ICG caused a change
in the treatment in 24% of the patients with dysp-
noea, while the brain natriuretic peptide caused
a change in the treatment in 11% of similar patients
[86]. Taler et al. [87] point to the usefulness of ICG
in the effective choice of antihypertensive medi-
cines in refractory arterial hypertension. Yung
et al. [26] confirmed the precision of ICG evalua-
tion of CO in patients with pulmonary hypertension
in a comparison between ICG, thermodilution (TD)
and the Fick method (F). The following correlation
was obtained: ICG vs. F 0.84, TD vs. F 0.89, ICG vs.
TD 0.80.
Impedance cardiography as a means
of pulmonary congestion assessment
ICG can be applied in haemodynamic monitor-
ing during diuretic therapy, as well as in the moni-
toring of patients during pleurocentesis and peri-
cardiocentesis [88]. TFC, the reverse of the chest
impedance, correlates closely with the amount of
fluid, both intravascular and extravascular, in the
chest. In patients after pleurocentesis Petersen et
al. showed a high degree of correlation between the
amount of fluid obtained and the change in chest
impedance [89]. Ebert et al. [90] showed a nearly
ideal linear correlation between changes in central
venous pressure and chest impedance.
Impedance cardiography after
orthotopic heart transplantation
A use for ICG is also found in the assessment
of patients after heart transplantation. According to
Nollerta, a diminution of 20% in ACI, the contract-
ibility parameter obtained by means of ICG, has
a sensitivity of 71% and a specificity of 100% in the
diagnosis of graft rejection. The number of heart
biopsies may also be reduced [24].
Impedance cardiography in heart failure
Data on haemodynamic parameters obtained by
means of ICG can be very helpful in the diagnosis
and treatment of heart failure patients [1, 23, 57,
91, 92, 94]. Albert et al. [85] have indicated the use-
fulness of ICG in cases of decompensated heart fail-
ure. Thanks to ICG the risks associated with cath-
eterisation of the pulmonary artery (infection, pul-
monary artery perforation and arrhythmia) may be
avoided. The low cost of this non-invasive mode of
measurement and the saving made on doctors and
nurses time are also relevant factors. A non-inva-
sive method of SV measurement has special signif-
icance for patients requiring intravenous medica-
tions, including inotropics.
Vijayaraghavan et al. [92] showed the prognos-
tic role of haemodynamic parameters obtained by
means of ICG in patients with chronic heart failure
and the strong dependence of changes in these pa-
rameters on functional class and quality of life.
Thanks to the ICG it is possible to investigate the
influence of medicines on haemodynamic parame-
ters, to assess the stability of the circulatory system
and to choose the best moment to start the therapy
(for instance beta-blocker or ACE-inhibitor thera-
pies) and to make a decision about the moment of
initiating catecholamines, determining the proper
dose and monitoring the efficiency of the treatment
in the case of decompensated heart failure [92, 94].
In many clinical studies ICG has been com-
pared to invasive methods (thermodilution and the
Fick method) [5, 19, 20, 23, 85] and non-invasive
methods (echocardiography) [19, 75, 95]. A close
correlation was obtained between results obtained
by ICG and invasive and non-invasive methods.
In a study of severe heart failure patients who
underwent pulmonary artery catheterisation Drazn-
er et al. [23] compared ICG with invasive methods.
In this study the correlation and the agreement
between SV as assessed by ICG and the Fick meth-
od were the same as between thermodilution and
the Fick method. They also showed that the Pear-
son correlation between ICG and thermodilution
was 0.76 for CO and 0.64 for CI. In the study by
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Albert et al. [85] the analogous correlations were
0.89 and 0.82 respectively. Thus the authors were
able to claim that the results obtained demonstrat-
ed the clinical usefulness of ICG in decompensated
heart failure patients.
Impedance cardiography versus other
methods of measuring haemodynamic
parameters
There are, however, studies which do not con-
firm this close correlation between ICG and inva-
sive methods. Engoren and Barbee [6] state that
measurement of SV by means of ICG, thermodilu-
tion and the Fick method are not comparable in
a heterogeneous group of the most seriously ill pa-
tients. In this study it was confirmed that in criti-
cally ill patients SV measurement by means of ICG
was not precise enough to replace thermodilution.
SV measurement can be determined by
echocardiography, which has shown a good corre-
lation with invasive methods [96, 97]. However, in
comparison with ICG echocardiography is consid-
erably more time-consuming and demands suitably
prepared staff [97]. Parrot et al. [95] compared ICG
with echocardiography, claiming that ICG deter-
mined changes in heart performance both easily and
cheaply. The authors showed a high degree of cor-
relation between changes in ICG parameters
(CI and STR) and ejection fraction (EF): CI vs. EF
0.85, STR vs. EF 0.73.
CO evaluation by means of the direct Fick
method is considered the most precise method, al-
though it is very time-consuming and involves the
necessity of receiving blood samples from the pul-
monary artery and arterial blood [19, 26]. The indi-
rect Fick method uses pulsoxymetry instead of this
[19], although it is still associated with the incon-
veniences of pulmonary artery catheterisation. The
Fick method is useless in patients with lung disease.
The method most often used is thermodilution [20],
but this has its own limitations; the variability of CO
measurements by thermodilution fluctuates between
5% and 20% and so, in order to proceed, the three
following measurements are necessary. These meas-
urements are averaged and cannot differ between
themselves by more than 10% [19]. Thermodilution
and the Fick method are expensive and can involve
the complications associated with pulmonary artery
catheterisation [20, 26, 98].
It is easier to measure SV by means of ICG than
by thermodilution, because it can be carried out
more quickly and without the risk of infection or the
other complications of pulmonary artery catheteri-
sation. Additionally, ICG enables SV to be moni-
tored in a continuous mode, unlike thermodilution,
in which single measurements are made with injec-
tions of fluids, which also add to the patients bur-
dens [99].
In literature we can find data showing better
results in the treatment of heart failure patients on
the basis of findings obtained from pulmonary ar-
tery catheterisation and also research which ques-
tions the usefulness, safety and the profitability of
the procedure, suggesting that it does not improve
the results of treatment and increases the compli-
cation rate and costs [57]. Silver et al. [57] point out
the high cost of pulmonary artery catheterisation,
claiming that it can be replaced by ICG; similar sug-
gestions emerge from the report by Hendrickson [98].
The economic aspects
of impedance cardiography
The cost of ICG is the expense of a single pur-
chase of the device and the cost of the electrodes,
which is low. There are no additional hidden costs,
no risks involved in the measurement and no pos-
sibility of complications during research. Addition-
ally, the results are obtained very quickly, it only
being necessary to stick on the electrodes, which
is undoubtedly beneficial for the patient and reduc-
es costs, speeding up the correct diagnosis and in-
itiation of treatment and thus shortening the length
of hospitalisation [98]. According to Clancy et al.
[100] the saving from using ICG exceeds 600 dol-
lars per patient in initial assessment, if the non-in-
vasive method is used instead of pulmonary artery
catheterisation. An additional saving is that of the
time of medical personnel [101]. The cost of treat-
ment of possible complications from pulmonary ar-
tery catheterisation also enters into the equation.
Should pulmonary artery
catheterisation be given up?
The high risk of using invasive methods is
a matter raised increasingly often [1]. There are
studies which show [102, 103] that the routine us-
age of pulmonary artery catheters in critically ill
patients can be linked to increased mortality and
raise the costs of treatment. In a study by Chittock
et al. [104] the use of a pulmonary artery catheter
was shown to be associated with a reduction in
mortality among the most seriously ill patients,
while in the remaining patients pulmonary artery
catheterisation increased mortality. In the year
1997 the Society of Critical Care Medicine ex-
pressed the opinion that the usage of pulmonary
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artery catheterisation in patients with heart failure
was of doubtful value and that randomised studies
are necessary to decide whether the advantages of
catheterising outweigh the risk [105]. This was why
the multicentre randomised study ESCAPE (Eval-
uation Study of Congestive Heart Failure and Pul-
monary Artery Catheterisation Effectiveness) was
designed. In the bioimpedance subgroup of the
ESCAPE study the usefulness of ICG in advanced
heart failure patients will be assessed [106].
The following are cited as complications of
pulmonary artery catheterisation: damage to the
wall of the pulmonary artery, pneumothorax, aero-
embolism, septicaemia, thrombophlebitis, phleboth-
rombosis, pulmonary infarction, endocarditis, ar-
rhythmia and even an increase in mortality [98].
Because of the lack prospective studies demonstrat-
ing the advantages of pulmonary artery catheteri-
sation, many doctors have given up this method.
Furthermore, not all patients hospitalised because
of aggravated heart failure are treated in an inten-
sive care unit where pulmonary artery catheterisa-
tion would be possible. In such situations ICG can
provide the requisite haemodynamic data in a gen-
eral department [57].
The above findings point to ICG as a method
which is simpler, quicker and, most importantly,
safer to use, as it is non-invasive and does not bur-
den the patient, while still being reliable.
In the last year two multicentre studies con-
cerning ICG use with patients with chronic heart
failure have been completed: the PREDICT study
(Prospective Evaluation and identification of De-
compensation by Impedance Cardiography Test)
and the BIG study (BioImpedance cardioGraphy).
The BIG study is part of the ESCAPE study and
their initial results have already been published
[107]. The data obtained from this research will help
to determine the role of ICG in the management of
heart failure patients.
Limitations of impedance cardiography
The results obtained may be inaccurate under
the following circumstances: when there is a con-
siderable degree of aortic insufficiency and septic
shock, when there is a considerable degree of arte-
rial hypertension (MAP > 130 mm Hg), when the
height of the patient is less than 120 cm or over
230 cm, when the weight is less than 30 kg or over
155 kg and when intra aortic balloon pump (IABP)
counterpulsation is employed [4, 26]. ICG is con-
traindicated in patients with pacemakers with
a sensor responsible for minute ventilation rate
switched on as the pacemaker rate in these patients
can increase because of the ICG signal. These pa-
tients must therefore have this function switched
off before measurement [108]. In patients with atrial
fibrillation or with numerous premature beats
a considerable arrhythmia can influence the ICG
signal and make the investigation impossible [41].
Summary
Over 40 years have passed since the technique
of measuring and monitoring the basic haemody-
namic parameters in humans by means of ICG was
formulated.
The progress of hardware and software, includ-
ing digital signal tooling and new algorithms, has
certainly improved the quality of the results obtained.
The accuracy and repeatability of the results
have been confirmed in comparative studies with
results obtained through invasive methods and
echocardiography. Not only are haemodynamic
changes monitored by means of ICG in intensive
care units, in operating theatres and at haemodial-
ysis stations, but repeated measurements also pro-
vide haemodynamic information during the treat-
ment of patients with hypertension and heart fail-
ure and pregnant women with cardiological
problems and gestosis. A single ICG investigation
makes a great contribution to the basic information
available about the circulatory system, which is
helpful in the initial evaluation of patients in a se-
vere general condition (for example in the admis-
sion room), and also makes it possible to make
a swift diagnosis of the cause of complaints such as
dyspnoea and hypotonia.
A particular application of ICG is the assess-
ment of haemodynamic parameters during the pro-
gramming of atrioventricular and CRT pacemakers.
Besides these uses, ICG is a valuable investigative
tool. It is defect-free and does not have pulmonary
artery pressure monitoring limitations. Moreover,
it is not as time-consuming as echocardiography and
the examination can be performed by trained tech-
nicians or nurses.
The main limitation on the widespread use of
this diagnostic and investigative method is the rel-
atively high price of the equipment. The appearance
on the market of new producers of such devices,
however, suggests that this method will become
widely used.
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